Amicus Therapeutics is in the Business of Healing and Restoring Hope in Patients with Rare and Orphan Diseases

Cranbury New Jersey harbors one of the fastest growing biotechnology firms, Amicus Therapeutics Inc. The company was incepted in the year 2002 and has since grown to command international recognition with offices in Germany, Italy, France, Netherlands, and Spain as well as its global headquarters in the United Kingdom. It is also publicly traded under the FOLD symbol by NASDAQ, having held its first public offer in 2007.

 

Committed to Heal

 

Amicus Therapeutics was founded with the mission of developing therapies and treatments for rare and orphan diseases with the aim of bringing forth healing. The firm is technologically equipped and driven by high level of innovation to achieve its goals (http://www.phillypurge.com/2017/08/02/amicus-therapeutics-the-fight-against-the-rare-diseases/). The rare diseases community is the major inspiration to the leadership of the company to keep endeavoring to soar higher in its discoveries. Led by the Chairman of the board and Chief Executive Officer, John F. Crowley, the company is prepared to reach greater heights in science. The professionals at the firm are dedicated to the wellbeing of the patients. To the firm, Patients are at the heart of what they do.

 

Medicines and Therapies

 

Amicus Therapeutics has made great progress in the development of treatments for various diseases. Migalastat, which is in the last stages of development, is a drug developed by Amicus Therapeutics to treat Fabry disease. The use of the medicine is based on the genetic diagnosis of the ailment. The company is also in the process of creating a new therapy for Pompe disease, Fabry disease, and Lysosomal Storage Disorders (LSD) named novel enzyme replacement therapy (ERT) products. This development is based on the firm’s Chaperone-Advanced Replacement Therapy (CHART™) and its biologics. Another development by the firm, which is almost complete is SD-101 (YahooFinance). This therapy will be hopefully the first to get to the market for the treatment of Epidermolysis Bullosa (EB), which is a genetic connective tissue disorder.

 

Giving Back

 

Amicus Therapeutics is very committed to the eradication of rare disease communities. The company generously supports individual as well as non-profit organizations in the healthcare sector, focused on rare and orphan diseases programs. It is dedicated to supporting advocacy and public education for these ailments.

Leave a Reply

Your email address will not be published. Required fields are marked *